

PRESS RELEASE

Exercise in Camurus' employee stock options program 2022/2026

Lund, Sweden — 11 June 2025 — As of 11 June 2025, a total of 507,966 options in Camurus AB's employee stock options program (ESOP) 2022/2026 have been exercised for the corresponding number of shares, at an exercise price of SEK 237.40 per share. Through the exercise of the employee stock options, Camurus receives a total of SEK 120,591,128.40.

A number of employees and senior executives of Camurus have participated in two forms of cashless exercise, where shares have been sold either in such number that was required to finance the subscription of new shares and taxes related to the ESOP exercise, or in such number of shares that corresponded to the number of employee stock options exercised by the participant.

The exercise period for ESOP 2022/2026 ends on 1 March 2026.

For more information

Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com

About Camurus

Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and [LinkedIn](#).

This information was submitted for publication at 8:30 am CEST on 11 June 2025.